Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response

Myong Jin Kim, Anne N. Nafziger, Clayton D. Harro, Harry L. Keyserling, Keith M. Ramsey, George L. Drusano, Joseph S. Bertino

Research output: Contribution to journalArticlepeer-review

Abstract

Sixty healthy nonresponders were randomized to receive intramuscular (IM) high dose hepatitis B virus (HBV) vaccine versus IM standard dose HBV vaccine plus granulocyte-macrophage colony-stimulating factor (GM-CSF) at 0-2 months. Antibody to hepatitis B surface antigen was measured 1 month after each dose and 3 months after the last dose. Two regimens were equivalent in eliciting seroprotection in nonresponders. Weight-height index (WHI) <39 and alanine transaminase (ALT) <39mg/dl predicted which nonresponders would seroconvert. A three-dose regimen of standard dose HBV vaccine plus GM-CSF may be a useful for seroprotection of healthy nonresponders.

Original languageEnglish (US)
Pages (from-to)1174-1179
Number of pages6
JournalVaccine
Volume21
Issue number11-12
DOIs
StatePublished - Mar 7 2003

Keywords

  • Granulocyte-macrophage colony-stimulating factor
  • Hepatitis B virus vaccine
  • Revaccination

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Revaccination of healthy nonresponders with hepatitis B vaccine and prediction of seroprotection response'. Together they form a unique fingerprint.

Cite this